A Double-blind, Randomized Phase II/III Trial of Active Immunotherapy with Globo H-KLH (OPT-822) in Subjects with Metastatic Breast Cancer

Trial Profile

A Double-blind, Randomized Phase II/III Trial of Active Immunotherapy with Globo H-KLH (OPT-822) in Subjects with Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Adagloxad simolenin (Primary) ; Cyclophosphamide; OPT 821
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors OBI Pharma; Optimer Pharmaceuticals
  • Most Recent Events

    • 02 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Aug 2019.
    • 09 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
    • 09 Sep 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top